138
Participants
Start Date
August 20, 2025
Primary Completion Date
August 20, 2027
Study Completion Date
August 20, 2028
Venetoclax
Venetoclax is administered orally at 400 mg/day for participants ≥14 years or 360 mg/m²/day for those aged 12-14 years, from day -14 to -8 before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Dose is adjusted to 100 mg/day (or 90 mg/m²/day for pediatric patients) if used with strong CYP3A4 inhibitors such as posaconazole.
None-placebo
Participants in this arm will not receive venetoclax as part of their conditioning regimen. They will undergo standard myeloablative conditioning with BUCY (busulfan, cyclophosphamide, and MeCCNU), prior to allogeneic hematopoietic stem cell transplantation. This arm serves as the active comparator to evaluate the addition of venetoclax in the experimental arm.
RECRUITING
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
The First Affiliated Hospital of Zhengzhou University
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Tongji Hospital
OTHER
The Children's Hospital of Zhejiang University School of Medicine
OTHER
Ruijin Hospital North Shanghai Jiao Tong University School of Medicine
UNKNOWN
First Affiliated Hospital of Zhejiang University
OTHER